aibioDermata shareholders approve warrant repricing and larger equity plan
Tickers DRMA
At its May 27, 2026 annual meeting, Dermata Therapeutics shareholders approved raising the share reserve of its 2021 equity plan to 402,214 shares and repricing warrants for up to 120,734 shares. Three Class II directors were elected.
Key facts
- Company
- Dermata Therapeutics, Inc. (NASDAQ: DRMA)
- News type
- Listings
- Primary source
- Dermata Therapeutics, Inc. 8-K (2026-05-27)
Dermata Therapeutics, Inc. (Nasdaq: DRMA) held its 2026 annual meeting of stockholders on May 27, 2026. Shareholders approved an amendment to the company's 2021 Omnibus Equity Incentive Plan that raises the shares available for issuance to 402,214. They also approved the repricing of warrants exercisable for up to 120,734 shares, and the issuance of shares underlying certain warrants in an amount equal to or in excess of 20% of the common stock outstanding. The company reported the results in a Form 8-K.
The filing lists the matters voted on at the meeting. These were the election of three Class II directors, ratification of the auditor, the Nasdaq approval for the warrant issuance, the warrant repricing, the plan amendment, and a proposal to adjourn the meeting if there were not enough votes. The Plan Amendment is filed as Exhibit 10.1.
What the company asked shareholders to approve
The Issuance Proposal covers shares underlying warrants issued under a securities purchase agreement dated as of December 23, 2025, and under an engagement letter between the company and H.C. Wainwright & Co., LLC, dated as of September 10, 2024, as amended. The approval was needed for purposes of complying with Nasdaq Listing Rule 5635(d).
The Warrant Repricing Proposal covers warrants exercisable for up to 120,734 shares issued to investors under securities purchase agreements, each dated as of January 21, 2025, and each amended on December 23, 2025. The Plan Amendment Proposal raises the maximum number of shares reserved under the 2021 plan to 402,214 shares.
Vote counts
A total of 2,374,471 common shares, or approximately 59% of the outstanding shares entitled to vote, were represented in person or by proxy. David Hale received 1,258,269 votes for and 47,546 withheld. Steven Mento, Ph.D. received 1,258,871 for and 46,944 withheld. Brittany Bradrick received 1,262,134 for and 43,681 withheld. Broker non-votes were 1,068,656 for each nominee.
Shareholders ratified CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 2,329,537 votes for, 43,122 against and 1,812 abstentions.
The Issuance Proposal drew 315,477 votes for, 22,696 against and 967,642 abstentions, with 1,068,656 broker non-votes. The Warrant Repricing Proposal drew 439,573 votes for, 21,203 against and 845,039 abstentions. The Plan Amendment Proposal drew 1,243,540 for, 47,441 against and 14,834 abstentions. The Adjournment Proposal drew 1,269,857 for, 21,137 against and 14,821 abstentions. The 8-K says each of the proposals was approved.
Company background
The 10-K describes the company's direction. In September 2025, management, with support from the board, decided to shift toward developing and distributing direct-to-consumer and business-to-business skincare products. The company had earlier reported statistically significant Phase 3 STAR-1 results for XYNGARI, a prescription candidate for moderate-to-severe acne, in March 2025.
The 10-K says the company plans to launch its first cosmetic product in the middle of 2026, with its first OTC acne product to follow shortly thereafter. It also describes a Bioneedle built from 100% Spongilla lacustris powder, combined with a fluidizing agent for once-weekly skin renewal.
Financial position
According to the 10-K, research and development expense was $2.9 million for 2025, compared with $8.2 million for 2024. Net loss was $7.6 million in 2025, compared with $12.3 million in 2024. Cash used in operations was $7.8 million in 2025 and $11.2 million in 2024.
This story uses only figures from filings made on or before May 27, 2026, so it does not cite later quarterly balances. The 8-K does not describe any new financing, and it does not give a cash balance.
The risks ahead
The approvals widen the room for new shares. The issuance vote covers shares underlying warrants in an amount equal to or in excess of 20% of the common stock outstanding, which can dilute current holders, and abstentions on that proposal outnumbered the votes for it. The company is still loss-making, with a net loss of $7.6 million and $7.8 million of cash used in operations in 2025. The 10-K sets a plan to launch a first cosmetic product in the middle of 2026, with an OTC acne product to follow.